Matthew Charles Baker
Internal Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Matthew Charles Baker’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A129608 · Current
Licensed to practise in California · since 2014 · expires 2028-04-30 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$25,884
Medicare paid this office $25,884 for 159 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 71 | $10,240 | $111 |
| Return visit (30+ min) | 48 | $5,073 | $77 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,856 | $155 |
| New patient visit (60+ min) | 14 | $1,822 | $130 |
| Short return visit (20+ min) | 19 | $1,521 | $63 |
See all 7 services
| Return visit (30+ min) | 71 | $10,240 | $111 |
| Return visit (30+ min) | 48 | $5,073 | $77 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,856 | $155 |
| New patient visit (60+ min) | 14 | $1,822 | $130 |
| Short return visit (20+ min) | 19 | $1,521 | $63 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 72 | $1,305 | $15 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 43 | $704 | $14 |
Who their Medicare patients are
159 Original Medicare patients in 2024. Average age 69 · Women 57% · Also on Medicaid 28% · Health risk score 1.73. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 68% · Diabetes 37% · Chronic kidney disease 34% · Coronary heart disease 27% · Heart failure 25% · Atrial fibrillation 21% · Depression 21% · Cancer 16% · COPD 16% · Stroke 9%.
The office billed $137,326, Medicare allowed $36,426 and paid $25,884; for 378 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 159 | 378 | 69 | 1.73 | $137,326 | $25,884 |
| 2023 | 141 | 254 | 71 | 1.72 | $113,328 | $19,657 |
| 2022 | 144 | 244 | 70 | 1.78 | $122,978 | $20,825 |
| 2021 | 165 | 290 | 69 | 1.71 | $177,495 | $25,253 |
| 2020 | 169 | 336 | 68 | 1.65 | $159,160 | $26,277 |
| 2019 | 99 | 175 | 68 | 1.57 | $27,419 | $14,106 |
| 2018 | 54 | 131 | 68 | 2.38 | $27,333 | $10,786 |
| 2017 | 29 | 41 | 70 | 1.99 | $5,641 | $2,708 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Return visit (30+ min) | 80 | $10,000 | $79 |
| Short return visit (20+ min) | 46 | $3,290 | $54 |
| New patient visit (60+ min) | 18 | $2,672 | $148 |
2022: 4 services
| Return visit (30+ min) | 89 | $11,472 | $87 |
| New patient visit (60+ min) | 24 | $3,777 | $157 |
| Short return visit (20+ min) | 34 | $2,039 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,628 | $65 |
2021: 3 services
| Return visit (30+ min) | 122 | $16,747 | $85 |
| New patient visit (60+ min) | 20 | $3,481 | $174 |
| Short return visit (20+ min) | 29 | $1,885 | $51 |
2020: 5 services
| Return visit (30+ min) | 106 | $12,903 | $67 |
| New patient visit (60+ min) | 36 | $5,449 | $151 |
| Long return visit (40+ min) | 18 | $1,873 | $104 |
| Return visit (30+ min) | 16 | $1,294 | $72 |
| Short return visit (20+ min) | 17 | $717 | $38 |
2019: 3 services
| Return visit (30+ min) | 57 | $6,737 | $65 |
| New patient visit (60+ min) | 31 | $4,542 | $147 |
| Short return visit (20+ min) | 14 | $557 | $37 |
2018: 2 services
| Return visit (30+ min) | 28 | $3,532 | $64 |
| Long return visit (40+ min) | 12 | $1,397 | $100 |
2017: 1 service
| Return visit (30+ min) | 19 | $1,834 | $68 |
Medicaid work
$877 in 2023
Medicaid paid $877 for 27 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 27 | $877 |
| 2023 | 27 | 1 | 12 | $877 |
| 2021 | 13 | 1 | 12 | $638 |
See the largest Medicaid services in earlier years
2021
| Return visit (30+ min) | 13 | $638 |
Drugs they prescribed that Part D paid
$1,076,253
Pharmacies billed $1,076,253 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 443) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
323 generic and fewer than 11 brand-name prescriptions · $1,076,253 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rinvoq | 53 | $392,307 | $7,402 |
| Humira(Cf) | 17 | $308,981 | $18,175 |
| Enbrel | 15 | $130,120 | $8,675 |
| Leflunomide | 45 | $3,677 | $82 |
| Methotrexate | 71 | $2,396 | $34 |
See all 9 drugs
| Rinvoq | 53 | $392,307 | $7,402 |
| Humira(Cf) | 17 | $308,981 | $18,175 |
| Enbrel | 15 | $130,120 | $8,675 |
| Leflunomide | 45 | $3,677 | $82 |
| Methotrexate | 71 | $2,396 | $34 |
| Cevimeline | 12 | $2,233 | $186 |
| Azathioprine | 30 | $1,446 | $48 |
| Prednisone | 76 | $705 | $9 |
| Hydroxychloroquine Sulfate | 26 | $631 | $24 |
Year by year
| 2024 | 443 | 84 | 0% (0) | None | $1,076,253 |
| 2023 | 509 | 76 | 0% (0) | None | $959,032 |
| 2022 | 457 | 73 | 0% (0) | None | $642,750 |
| 2021 | 547 | 89 | 0% (0) | 24% | $634,734 |
| 2020 | 492 | 73 | 0% (0) | None | $562,155 |
| 2019 | 361 | 46 | 0% (0) | None | $408,753 |
| 2018 | 271 | 34 | 0% (0) | 25% | $250,300 |
| 2017 | 65 | 22 | 0% (0) | 34% | $72,117 |
| 2016 | 11 | None | 0% (0) | None | $1,552 |
| 2015 | 74 | 20 | 0% (0) | 18% | $6,368 |
| 2014 | 331 | 26 | 5% (17) | 14% | $22,310 |
| 2013 | 408 | 29 | 10% (40) | None | $21,686 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Rinvoq | 55 | $364,161 | $6,621 |
| Humira | 13 | $97,584 | $7,506 |
| Enbrel | 12 | $92,247 | $7,687 |
| Leflunomide | 44 | $3,428 | $78 |
| Azathioprine | 27 | $2,915 | $108 |
| Methotrexate | 67 | $2,898 | $43 |
| Hydroxychloroquine Sulfate | 60 | $2,557 | $43 |
| Cevimeline | 11 | $1,993 | $181 |
| Prednisone | 99 | $1,140 | $12 |
| Diclofenac | 16 | $584 | $37 |
2022: 10 drugs
| Rinvoq | 41 | $251,405 | $6,132 |
| Humira | 16 | $109,388 | $6,837 |
| Enbrel | 15 | $106,191 | $7,079 |
| Leflunomide | 26 | $2,766 | $106 |
| Hydroxychloroquine Sulfate | 60 | $2,671 | $45 |
| Cevimeline | 11 | $2,547 | $232 |
| Methotrexate | 55 | $2,543 | $46 |
| Azathioprine | 31 | $2,079 | $67 |
| Prednisone | 91 | $1,336 | $15 |
| Diclofenac | 25 | $481 | $19 |
2021: 13 drugs
| Rinvoq | 33 | $188,818 | $5,722 |
| Humira | 29 | $183,800 | $6,338 |
| Enbrel | 19 | $115,592 | $6,084 |
| Xeljanz Xr | 11 | $55,961 | $5,087 |
| Actemra | 11 | $34,934 | $3,176 |
| Leflunomide | 38 | $5,302 | $140 |
| Methotrexate | 88 | $3,812 | $43 |
| Hydroxychloroquine Sulfate | 50 | $2,960 | $59 |
| Azathioprine | 32 | $1,938 | $61 |
| Prednisone | 113 | $1,448 | $13 |
| Cevimeline | 13 | $1,109 | $85 |
| Allopurinol | 19 | $462 | $24 |
| Diclofenac | 13 | $279 | $21 |
2020: 12 drugs
| Humira | 27 | $191,213 | $7,082 |
| Enbrel | 17 | $108,911 | $6,407 |
| Rinvoq | 18 | $93,138 | $5,174 |
| Xeljanz Xr | 16 | $78,303 | $4,894 |
| Mycophenolate Mofetil | 11 | $4,522 | $411 |
| Leflunomide | 26 | $3,585 | $138 |
| Methotrexate | 79 | $3,477 | $44 |
| Hydroxychloroquine Sulfate | 46 | $2,584 | $56 |
| Azathioprine | 44 | $2,169 | $49 |
| Cevimeline | 14 | $1,158 | $83 |
| Prednisone | 90 | $896 | $10 |
| Etodolac | 11 | $478 | $43 |
2019: 10 drugs
| Humira | 17 | $100,747 | $5,926 |
| Xeljanz Xr | 19 | $88,431 | $4,654 |
| Enbrel | 12 | $55,649 | $4,637 |
| Actemra | 13 | $27,486 | $2,114 |
| Leflunomide | 24 | $2,962 | $123 |
| Hydroxychloroquine Sulfate | 16 | $2,689 | $168 |
| Azathioprine | 41 | $2,598 | $63 |
| Methotrexate | 45 | $2,291 | $51 |
| Cevimeline | 12 | $1,090 | $91 |
| Prednisone | 87 | $989 | $11 |
2018: 7 drugs
| Xeljanz Xr | 21 | $88,387 | $4,209 |
| Enbrel | 13 | $61,468 | $4,728 |
| Hydroxychloroquine Sulfate | 24 | $3,469 | $145 |
| Methotrexate | 40 | $2,934 | $73 |
| Leflunomide | 23 | $2,197 | $96 |
| Azathioprine | 22 | $1,382 | $63 |
| Prednisone | 59 | $604 | $10 |
2017: 1 drug
| Methotrexate | 11 | $1,176 | $107 |
2014: 10 drugs
| Metoprolol | 21 | $653 | $31 |
| Atorvastatin | 18 | $466 | $26 |
| Gabapentin | 18 | $444 | $25 |
| Methadone | 16 | $361 | $23 |
| Tamsulosin | 16 | $270 | $17 |
| Diltiazem 24hr Er | 12 | $212 | $18 |
| Omeprazole | 12 | $191 | $16 |
| Amlodipine Besylate | 25 | $158 | $6 |
| Lisinopril | 16 | $128 | $8 |
| Hydrochlorothiazide | 11 | $67 | $6 |
2013: 13 drugs
| Atorvastatin | 20 | $1,237 | $62 |
| Clopidogrel | 16 | $961 | $60 |
| Metoprolol | 24 | $754 | $31 |
| Methadone | 33 | $591 | $18 |
| Omeprazole | 23 | $365 | $16 |
| Nifedipine Er | 14 | $271 | $19 |
| Warfarin | 36 | $259 | $7 |
| Sumatriptan | 13 | $222 | $17 |
| Amlodipine Besylate | 25 | $206 | $8 |
| Diltiazem 24hr Er | 11 | $194 | $18 |
| Simvastatin | 14 | $147 | $10 |
| Tamsulosin | 12 | $142 | $12 |
| Lisinopril | 17 | $130 | $8 |
Money from drug and device companies
$25,981 in 2025
| 2025 | 4 | 24 | $24,495 | $25,981 |
| 2024 | 2 | 5 | $13,272 | $13,272 |
| 2023 | 1 | 9 | $8,550 | $9,676 |
| 2022 | 1 | 1 | $2,250 | $2,250 |
| 2021 | 3 | 3 | $1,800 | $1,958 |
| 2020 | 1 | 1 | None | $81 |
| 2019 | 2 | 3 | None | $127 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Argenx US | Vyvgart | $10,150 | 10 payments
|
| Neurocrine BioSciences | None | $7,800 | 7 payments
|
| Amgen | Uplizna | $6,632 | 6 payments
|
| Eli Lilly and | None | $1,400 | 1 payment
|
See all 24 published payments
| Neurocrine BioSciences | Consulting · 2025-12-18 | None | $1,400 |
| Amgen | Consulting · 2025-12-16 | Uplizna | $912 |
| Amgen | Consulting · 2025-11-11 | Uplizna | $3,648 |
| Neurocrine BioSciences | Consulting · 2025-10-28 | None | $600 |
| Amgen | Meals · 2025-10-24 | Uplizna | $133 |
| Amgen | Meals · 2025-10-24 | Uplizna | $133 |
| Amgen | Meals · 2025-10-24 | Uplizna | $133 |
| Argenx US | Consulting · 2025-09-11 | Vyvgart | $8,750 |
| Argenx US | Meals · 2025-09-06 | Vyvgart Hytrulo | $20 |
| Argenx US | Travel · 2025-09-06 | Vyvgart Hytrulo | $70 |
| Argenx US | Travel · 2025-09-06 | Vyvgart Hytrulo | $384 |
| Argenx US | Travel · 2025-09-06 | Vyvgart Hytrulo | $217 |
| Argenx US | Meals · 2025-09-06 | Vyvgart Hytrulo | $75 |
| Argenx US | Travel · 2025-09-06 | Vyvgart Hytrulo | $126 |
| Argenx US | Travel · 2025-09-05 | Vyvgart Hytrulo | $98 |
| Argenx US | Meals · 2025-09-05 | Vyvgart Hytrulo | $98 |
| Neurocrine BioSciences | Consulting · 2025-09-04 | None | $700 |
| Neurocrine BioSciences | Consulting · 2025-07-24 | None | $1,100 |
| Neurocrine BioSciences | Consulting · 2025-07-09 | None | $900 |
| Eli Lilly and | Consulting · 2025-06-20 | None | $1,400 |
| Neurocrine BioSciences | Consulting · 2025-05-21 | None | $1,400 |
| Amgen | Consulting · 2025-05-06 | Uplizna | $1,672 |
| Argenx US | Consulting · 2025-04-17 | Vyvgart Hytrulo | $313 |
| Neurocrine BioSciences | Consulting · 2025-03-19 | None | $1,700 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $13,272
| Amgen | Uplizna | $10,147 | 4 payments
|
| Argenx US | None | $3,125 | 1 payment
|
2023: $9,676
| Horizon Therapeutics plc | Uplizna | $9,676 | 9 payments
|
2022: $2,250
| Horizon Therapeutics plc | Uplizna | $2,250 | 1 payment
|
2021: $1,958
| Horizon Therapeutics plc | Uplizna | $1,800 | 1 payment
|
| Gilead Sciences | None | $116 | 1 payment
|
| Eli Lilly and | None | $41 | 1 payment
|
2020: $81
| Amgen | Enbrel | $81 | 1 payment
|
2019: $127
| Eli Lilly and | None | $90 | 2 payments
|
| Amgen | Evenity | $37 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ARGENX US, INC. · Vyvgart Hytrulo · 2025 | Their institution | $401,568 |
| GENZYME CORPORATION · A Phase II, Single-Site, Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis · 2022 | Their institution | $378,320 |
| Amgen Inc. · P3 Inebilizumab in Igg4-Related Disease · 2024 | Their institution | $84,995 |
| Horizon Therapeutics plc · A Phase 3, Randomized, Double-Blind, Multicenter, Placebo Controlled Study of Inebilizumab Efficacy and Safety in Igg4-Related Disease · 2023 | Their institution | $73,997 |
| Horizon Therapeutics plc · A Phase 3, Randomized, Double-Blind, Multicenter, Placebo Controlled Study of Inebilizumab Efficacy and Safety in Igg4-Related Disease · 2022 | Their institution | $72,111 |
| Horizon Therapeutics plc · Vib0551.P3.S2 · 2021 | Their institution | $38,056 |
| Amgen Inc. · P3 Inebilizumab in Igg4-Related Disease (Mitigate) · 2025 | Their institution | $23,541 |
| Eli Lilly and Company · 2023 | This clinician | $20,000 |
| SANOFI US SERVICES INC. · An Open Label, Two-Arm Study To Evaluate the Effect of Rilzabrutinib (Prn1008) on Safety and Disease Activity in Patients With Igg4-Related Disease · 2022 | Their institution | $8,828 |
| AbbVie Inc. · Rinvoq · 2020 | Their institution | $7,007 |
| GlaxoSmithKline, LLC. · A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An · 2021 | Their institution | $4,286 |
| ABBVIE INC. · A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (Abt-494) To Placebo in Subjects With Active Psoriatic Arthritis Who Have A History of Inadequate Response To at Least One Biologic Disease Modifying Anti-Rheumatic Drug (Bdmard) · 2021 | Their institution | $3,868 |
| ABBVIE INC. · A Study Comparing Upadacitinib (Abt-494) To Placebo in Participants With Active Psoriatic Arthritis Who Have A History of Inadequate Response To at Least One Biologic Disease Modifying Anti-Rheumatic Drug (Bdmard) · 2024 | Their institution | $1,478 |
| ABBVIE INC. · A Study Comparing Upadacitinib (Abt-494) To Placebo in Participants With Active Psoriatic Arthritis Who Have A History of Inadequate Response To at Least One Biologic Disease Modifying Anti-Rheumatic Drug (Bdmard) · 2022 | Their institution | $60 |
Professional record
- NPI
- 1518252204
- Licence
- CA A129608California A129608: Current · expires 2028-04-30
- Trained
- Harvard Medical School, 2011
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-06-10
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.